The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | Cemiplimab prospects: CRC, CSCC & HNSCC
From the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Hani Babiker, MD, of the University of Arizona Cancer Center, Tucson, AZ, discusses the pathobiology of and prospects for selective inhibitors of nuclear export (SINE) in colorectal cancer, before discussing the results of the PD-1 checkpoint inhibitor, cemiplimab, for unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (NCT02383212). He then presents the exciting results from a Phase I trial of cemiplimab for metastatic head and neck squamous cell carcinoma (NCT02383212).
